Drug Pipeline Database & Screener

Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-25 minutes.

Showing 570 companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$70.19
-0.08  -0.11%
1.5 billion
$103.8 billion
2.45
07/16/2019
Tap to view 40 drugs
Drug Indication Stage News
Risankizumab Ulcerative colitis Phase 3 Phase 3 trial to be initiated 1H 2018.
Depatuxizumab mafodotin ABT-414 Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017.
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Partial clinical hold lifted June 24, 2019.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial planned.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial planned.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis Approved FDA approval announced April 23, 2019.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
Risankizumab Psoriatic Arthritis Phase 2b Phase 3 trial planned for 2018.
ABT-494 Crohn’s Disease Phase 3 Phase 3 trial initiated late 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494 Atopic Dermatitis Phase 3 Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids NDA Filing NDA filing due mid-2019.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
ABT-494 upadacitinib Rheumatoid arthritis PDUFA priority review PDUFA date under priority review estimated at August 19, 2019.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 data due 2020.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML Approved FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 2/3 Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab Chronic Lymphocytic Leukemia Phase 3 FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva Chronic lymphocytic leukemia (CLL) Phase 3 Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta MIRROS Acute myeloid leukemia (AML) Phase 3 Phase 3 data due 2019.
Venclexta BELLINI Multiple myeloma Phase 3 Phase 3 primary endpoint met.
Venetoclax and obinutuzumab Chronic lymphocytic leukemia sNDA Filing sNDA filing announced June 4, 2019.
$4.15
-0.07  -1.66%
49.2 million
$204 million
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 interim data due 2H 2019.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Phase 3 trial to be initiated mid-2019.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 safety and tolerability data to be presented at WORLDSymposium February 6, 2019.
ABO-202 CLN1 disease (Infantile Batten disease) Phase 1/2 Phase 1/2 trial planned. Timing to be announced later in 2019.
$6.87
-0.09  -1.32%
1.5 million
$10 million
07/16/2019
Tap to view 1 drug
$2.26
-0.08  -3.42%
58 million
$131.1 million
07/16/2019
Tap to view 5 drugs
$26.48
-0.23  -0.88%
144.2 million
$3.8 billion
07/16/2019
Tap to view 7 drugs
Drug Indication Stage News
Pimavanserin - CLARITY-2 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - Advance Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 data due year-end 2019.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data due mid-2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 interim data 2H 2019 with final data due 2020.
Trofinetide Rett Syndrome Phase 3 Phase 3 trial to be initiated 4Q 2019.
$3.25
-0.04  -1.36%
10.1 million
$32.8 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome CRL CRL issued June 25, 2019.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) Phase 2 Pivotal bridging trial to be initiated 4Q 2019 with NDA filing 1Q 2020.
$2.46
-0.01  -0.40%
138.7 million
$341.3 million
07/16/2019
Tap to view 6 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 End of Phase 2 meeting 4Q 2019.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 final data presented at EHA June 15, 2019.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
ACH-4471 C3 glomerulopathy (C3G) Phase 2 End of Phase 2 meeting 4Q 2019.
ACH-5228 Healthy volunteers Phase 1 Phase 1 multiple ascending dose trial to be completed 2019.
$1.82
-0.03  -1.64%
7.8 million
$14.2 million
07/16/2019
Tap to view 1 drug
$5.59
+0.08  +1.45%
67.6 million
$377.7 million
07/16/2019
Tap to view 7 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705) Alzheimer’s disease Phase 2 Phase 2 data due 3Q 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 interim data due 2019.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
ACI-24 Alzheimer’s disease Phase 2 Phase 2 trial initiation announced August 20, 2018.
MTAU9937A Alzheimer’s disease Phase 2 Phase 2 trial initiation announced February 20, 2019.
ACI-35 Alzheimer’s disease Phase 1b Phase 2 trial planned for 1H 2019.
$6.50
-0.06  -0.91%
48.1 million
$312.8 million
07/16/2019
Tap to view 6 drugs
$2.19
-0.04  -1.79%
41.3 million
$90.4 million
07/16/2019
Tap to view 9 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Phase 2 open label 6-month data due mid-2019.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 data due 2H 2019.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data due 2H 2019.
ATI-502 AA-202 Topical - PK/safety Alopecia areata Phase 2 Phase 2 interim data released June 28, 2018.
ATI-502 (ATI-50002-AGA-201) - open label Androgenetic alopecia (AGA) - Hair loss Phase 2 Phase 2 6-month data noted increase in hair count of 8.6 hairs/cm2. 12 month data due YE 2019.
ATI-502 (AD-201 Topical) Atopic dermatitis (AD) Phase 2 Phase 2 data due mid-2019.
ATI-450 Rheumatoid arthritis (RA) Phase 1/2 Phase 1/2 trial to be initiated 2H 2019.
$2.78
-0.06  -1.99%
78.9 million
$219.7 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.
$1.42
-0.01  -0.70%
79.1 million
$110.9 million
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRILOGY 1 and 2) Hypertriglyceridemia Phase 3 Phase 3 top-line data due in December 2019 (1) and January 2020 (2).
$3.52
+0.02  +0.57%
104.7 million
$368.6 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
MAGE-A4 (ADP-A2M4) Soild tumors Phase 1 Phase 1 update due 2H 2019.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 update due 1H 2020.
MAGE-A10 (ADP-A2M10) Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 data May 6, 2019 noted 4/7 stable disease. No partial responses. Update due 2H 2019.
MAGE-A4 (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 trial to be initiated later in 2019.
MAGE-A4 (ADP-A2M4CD8 - SURPASS) Soild tumors Phase 1 Phase 1 trial to be initiated in 2019 with data due in 2020.
$1.99
+0.01  +0.51%
10.2 million
$20.3 million
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
AD04 Alcohol use disorder Phase 3 Phase 3 data due in 2020. Data from second Phase 3 trial for U.S. required endpoint due 2022.
$4.07
+0.03  +0.82%
59.3 million
$241.6 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL Response to Complete Response Letter submitted January 7, 2019.
$1.32
-0.14  -9.59%
47.6 million
$62.9 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection Opioid overdose PDUFA PDUFA date October 31, 2019.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
$6.02
+0.08  +1.35%
27.5 million
$165.7 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Further development deferred - noted May 9, 2019.
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data due 4Q 2019.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$38.80
+0.66  +1.73%
123.2 million
$4.8 billion
07/16/2019
Drug Indication Stage News
$1.53
+0.01  +0.60%
80 million
$122.4 million
07/16/2019
Tap to view 10 drugs
Drug Indication Stage News
ADU-S100 Solid tumors or lymphomas Phase 1b Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Noted December 12, 2017 that development to be discontinued.
pLADD Colorectal Cancer Phase 1 Phase 1 ongoing.
pLADD Colorectal Cancer Phase 1 Phase 1 ongoing.
ADU-214 with Nivolumab Non-Small Cell Lung Cancer Phase 1/2 Phase 1b initiation announced June 7, 2018.
ADU-S100 and Spartalizumab Solid tumors or lymphomas Phase 1b Phase 1b presentation at ASCO June 2, 2019 noted 1 CR and 2/8 PRs among TNBC patients. 2/25 PRs among melanoma patients.
ADU-S100 and ipilimumab Melanoma Phase 1 Phase 1 commencement of dosing announced February 11, 2019.
BION-1301 IgA Nephropathy Phase 1 Phase 1 initial data in healthy volunteers expected in 1H 2020 and IgAN patients in 2H 2020.
$16.09
+0.63  +4.08%
63.8 million
$1 billion
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Development to be discontinued - noted November 1, 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022 Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 24-Week data from first cohort to be presented September 12, 2019.
$1.46
-0.11  -7.01%
8 million
$11.7 million
07/16/2019
Tap to view 7 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 monotherapy, overall survival was 8.5 months, combo with Keytruda 23 months.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-HOT 503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 preliminary data due 2H 2019.
$24.80
-0.45  -1.78%
45.9 million
$1.1 billion
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
Roclatan Glaucoma Approved FDA Approval announced March 12, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1/2 Phase 1/2 trial to be initiated 2Q 2019.
AR-1105 Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 trial initiated March 2019.
$2.67
-0.01  -0.37%
16.4 million
$43.9 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$3.14
-0.01  -0.32%
62.4 million
$196 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive lymphoma Phase 1/2 Phase 1b/2a updated data at ICML June 19, 2019 noted 50% ORR.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 program terminated - noted May 22, 2019.
AFM13 Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF) Phase 2 Phase 2 trial to be initiated 2H 2019.
$2.50
-0.04  -1.57%
134.3 million
$335.6 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
AGEN2034 and AGEN1884 Solid tumors Phase 1/2 Phase 1/2 data due 2019.
AGEN1884 (anti-CTLA-4) Solid cancers Phase 1 Phase 1 data due 2019.
Shingrix Shingles Approved Approval announced October 20, 2017.
AGEN2034 (anti-PD-1) Cervical cancer Phase 1/2 Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN1181 - 2nd gen CTLA Advanced cancer Phase 1 Phase 1 data due 2019.
$46.20
+0.03  +0.06%
58.7 million
$2.7 billion
07/16/2019
Tap to view 16 drugs
Drug Indication Stage News
AG-348 - Mitapivat Thalassemia Phase 2 Phase 2 data due 2H 2019.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE) Pyruvate kinase deficiency Phase 3 Phase 3 enrolment to be completed 2019.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 data released May 15, 2019 met primary endpoint. Data to be presented at ESMO September 27-October 1, 2019.
AG-120 Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib Frontline AML with IDH1 or IDH2 mutation Phase 1 Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270 Solid tumors Phase 1 Phase 1 dose escalation data due 2H 2019.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 trial to be initiated YE 2019.
Ivosidenib Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Ivosidenib and Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 data presented at ASCO June 3, 2019, 2:15pm.
Ivosidenib IDH1 mutant newly diagnosed AML ineligible for standard therapies Phase 1 Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza) Newly diagnosed AML with an IDH1 mutation Phase 1 Phase 1 updated data at ASCO June 3, 2019. 61% CR rate.
$6.85
+0.07  +1.03%
28.8 million
$197.6 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102) Arginase I deficiency Phase 1/2 Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021. Phase 1/2 further data due September 2019.
AEB1102 Solid tumors Phase 1 Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102) Solid tumors Phase 1 Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 2 Phase 1/2 top-line data due 1H 2020.
$165.95
-0.13  -0.08%
327.8 million
$54.4 billion
0.8
07/16/2019
Tap to view 32 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX Overactive Bladder (OAB) Phase 2 Phase 2 trial to be completed 2H 2019.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Brazikumab Crohn's disease Phase 3 Phase 3 data due 2020.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist Psoriasis Phase 2b Phase 2b trial ongoing.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 data released January 24, 2019 - primary endpoint met.
ATOGEPANT Chronic migraine Phase 3 Phase 3 data due in 2020.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 top-line data due 2020.
ESMYA (ulipristal acetate) Uterine Fibroids CRL CRL issued August 21, 2018.
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2020.
ABICIPAR Age-related macular degeneration (AMD) BLA Filing BLA filing due 2H 2019.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Sarecycline Severe acne vulgaris Approved FDA Approval announced October 2, 2018.
Cariprazine Bipolar I Depression PDUFA FDA Approval announced May 28, 2019.
UBROGEPANT Migraine PDUFA NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
Brazikumab Ulcerative colitis Phase 2/3 Phase 2/3 data due 2020.
Brimo DDS Geographic atrophy Phase 3 Phase 3 trial to be initiated 2H 2018.
Bimatoprost Open-angle glaucoma or ocular hypertension NDA Filing NDA filing due estimate 3Q 2019.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) - pediatric Approved FDA Approval announced March 18, 2019.
Botox Lower limb spasticity PDUFA PDUFA date 4Q 2019.
Botox Upper limb spasticity Approved FDA Approval announced June 21, 2019.
AGN-241751 Major Depressive Disorder (MDD) Phase 2 Phase 2 top-line data due 2H 2019.
Presbysol Presbyopia Phase 3 Phase 3 top-line data due 2020.
RAPASTINEL Depression Phase 2 Phase 2 monotherapy interim analysis 2H 2019.
$1.28
-0.06  -4.25%
43.7 million
$56.1 million
07/16/2019
Tap to view 1 drug
$3.75
-0.05  -1.32%
18.2 million
$68.1 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 six-month data for the dose escalation portion due 4Q 2019.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AAV-based gene therapy X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Phase 1/2 dose escalation data due 3Q 2019. Expansion data due 4Q 2019.
$18.98
-0.01  -0.05%
62.5 million
$1.2 billion
07/16/2019
Tap to view 7 drugs
Drug Indication Stage News
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 trial met primary endpoint - March 25, 2019.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 Peanut Allergy PDUFA PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019.
AR 201 Egg Allergy Phase 2 Phase 2 trial to be initiated mid-2019.
AR 301 Walnut Allergy Phase 2 Phase 2 trial to be initiated 2H 2019.
AR101 with adjunctive dupilumab Peanut Allergy Phase 2 Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON Peanut Allergy Phase 3 Phase 3 initiation announced December 19, 2018.
$4.21
-0.06  -1.41%
117.9 million
$496.2 million
07/16/2019
Tap to view 6 drugs
Drug Indication Stage News
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated in 2019.
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 trial data due 2019.
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 data due mid-2020.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
$23.44
-0.04  -0.17%
92.8 million
$2.2 billion
07/16/2019
Tap to view 9 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2 Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx Hyperlipoproteinemia and established cardiovascular disease Phase 2b Phase 2b data due 1H 2020.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2 data presented at AHA November 2018 - endpoints met.
Inotersen (IONIS-TTRRx) NEURO-TTR - familial amyloid polyneuropathy (FAP). Approved FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) CRL CRL issued August 27, 2018.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 data due mid-2019.
AKCEA-TTR-LRx hATTR Amyloidosis Phase 1/2 Phase 1/2 data and Phase 3 trial initiation due 2H 2019.
$20.60
-0.15  -0.71%
27 million
$557.2 million
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
AKR-001 Nonalcoholic steatohepatitis (NASH) Phase 2a Phase 2a data due 1H 2020.
$1.87
  +0.00%
16.5 million
$30.9 million
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
Coversin - CAPSTONE Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 staged readouts - no definitive timeline set by company. 2019?
Coversin Atopic keratoconjunctivitis Phase 1/2 Phase 1/2 Part B data due 4Q 2019.
Coversin Bullous Pemphigoid Phase 2 Phase 2 further data due 4Q 2019.
Coversin Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 2 Pivotal HSCT-TMA trial to be initiated 4Q 2019.
$29.09
+0.25  +0.86%
12 million
$350.2 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
Odevixibat (A4250) - PEDFIC- 1 Liver disease Phase 3 Phase 3 top-line data due mid-2020.
Elobixibat Nonalcoholic steatohepatitis (NASH) Phase 2 Phase 2 data due mid-2020.
Odevixibat (A4250) Biliary atresia Phase 3 Phase 3 trial planned for 2020.
$11.11
-0.27  -2.37%
83.5 million
$927.7 million
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
Eptinezumab ALD403 Frequent episodic migraine PDUFA PDUFA date February 21, 2020.
ALD403 Chronic Migraine Phase 2b Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.
Eptinezumab Acute migraine Phase 3 Phase 3 trial to be initiated 2H 2019.
$5.66
-0.02  -0.35%
27.5 million
$155.6 million
07/16/2019
Tap to view 6 drugs
Drug Indication Stage News
ADX-102 - topical ocular reproxalap - RENEW Dry eye syndrome Phase 3 Phase 3 initiation announced April 2, 2019.
Reproxalap (ADX-102) Allergic conjunctivitis Phase 3 Phase 3 data March 25, 2019 - primary endpoint met.
ADX-102 reproxalap Noninfectious anterior uveitis Phase 3 Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102) Sjögren-Larsson Syndrome (SLS) Phase 3 Phase 3 initial data due in 2H 2019.
ADX-1612 (ganetespib) Mesothelioma Phase 2 Phase 2 trial to be initiated 2H 2019.
ADX-2191 Proliferative vitreoretinopathy (PVR) Phase 3 Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
$18.97
-0.03  -0.16%
68.9 million
$1.3 billion
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
AL001 Frontotemporal Dementia Phase 1 Phase 1b trial to be initiated 1H 2019.
AL002 Alzheimer’s disease Phase 1 Phase 1 initiation of dosing announced May 6, 2019.
AL003 Alzheimer’s disease Phase 1 Phase 1 trial initiation announced April 3, 2019.
$0.88
+0.01  +1.15%
71 million
$62.5 million
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$23.44
+0.1  +0.43%
156.9 million
$3.7 billion
07/16/2019
Tap to view 13 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early Schizophrenia - young adults Phase 3 Phase 3 data due early 2020.
ALKS 3831 - ENLIGHTEN-2 Schizophrenia, bipolar NDA Filing Noted July 15, 2019 that NDA filing due 4Q 2019 will include Bipolar I indication
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098) Multiple sclerosis (MS) PDUFA NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461 Major depressive disorder CRL CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1 Solid tumors Phase 1 Phase 1/2 commences expansion phase of trial - June 12, 2019.
Aristada and Invega Sustenna Schizophrenia Phase 3 Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2 Solid tumors Phase 1 Phase 1 initiation announced February 26, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 Phase 3 top-line data due mid-2019.
$35.16
-0.8  -2.21%
43.1 million
$1.5 billion
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1 Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002 Indolent Systemic Mastocytosis Phase 1 Phase 1 data released February 19, 2019.
AK002 Chronic Urticaria Phase 2 Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002 Eosinophilic Gastritis Phase 2 Phase 2 top-line data due mid-2019.
$27.12
+0.07  +0.28%
121.5 million
$3.3 billion
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 update at ASH December 3, 2018 noted 86% CR/CRi.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Phase 1 update 2019.
ALLO-715 Multiple myeloma Phase 1/2 Phase 1/2 trial to be initiated in 2H 2019.
ALLO-501 - ALPHA Non-Hodgkin lymphoma (NHL) Phase 1 Phase 1 initial data due 1H 2020.
$4.91
-0.07  -1.31%
20.8 million
$102.1 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Data from first Phase 3 trial due 2H 2019.
Reloxaliase ALLN-177 (Study 206) Primary hyperoxaluria Phase 2 Phase 2 top-line data due 2H 2019.
Reloxaliase ALLN-177 (URIROX-2) Enteric Hyperoxaluria Phase 3 Phase 3 trial initiated 4Q 2018.
$73.26
+0.47  +0.65%
106.5 million
$7.8 billion
07/16/2019
Tap to view 16 drugs
Drug Indication Stage News
Fitusiran Hemophilia A and B Phase 2 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran Acute hepatic porphyrias NDA Filing Rolling NDA completion announced June 5, 2019.
Inclisiran - ORION-9 Hypercholesterolemia Phase 3 Phase 3 data 3Q 2019.
ALN-HBV02 (VIR-2218)) Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A Primary Hyperoxaluria Type 1 (PH1) Phase 3 Phase 3 data due late-2019.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran) IgA nephropathy Phase 2 Phase 2 trial to be initiated.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 first read-out expected 2H 2019
ALN-TTRsc02 - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 trial enrolling - noted December 6, 2018.
Inclisiran - ORION-10 Cardiovascular disease (ASCVD) Phase 3 Phase 3 sata due 3Q 2019.
Inclisiran - ORION 11 Cardiovascular disease (ASCVD) Phase 3 Phase 3 data due 3Q 2019.
ALN-AAT02 alpha-1 anti-trypsin deficiency-associated liver disease Phase 1/2 Phase 1/2 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-B Primary Hyperoxaluria Type 1 Phase 3 Phase 3 top-line data due mid-2020.
Patisiran APOLLO-B Wild-type ATTR amyloidosis patients with cardiomyopathy Phase 3 Phase 3 trial to be initiated mid-2019.
Lumasiran (ALN-GO1) ILLUMINATE-C Impaired renal function Phase 3 Phase 3 trial to be initiated mid-2019.
ALN-AGT Hypertension Phase 1 Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
$4.21
  +0.00%
18.6 million
$78.2 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101 Healthy volunteers Phase 1 Phase 1 safety trial initiation announced February 11, 2019.
$0.58
-0.02  -3.52%
26.7 million
$15.5 million
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C) Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b data due 4Q 2019.
ALRN-6924 and IBRANCE (palbociclib) Solid tumors Phase 2a Phase 2a preliminary data due at ESMO Sept 27-Oct 1, 2019 with final data due 2H 2020.
ALRN-6924 and Paclitaxel Breast cancer Phase 1 Phase 1 has been initiated.
ALRN-6924 Small Cell Lung Cancer (SCLC) Phase 1/2 Phase 1b/2 trial to commence September 2019 with data due 1Q 2020.
$2.45
-0.02  -0.94%
13.5 million
$32.9 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 1 Phase 2 trial planned for 2020.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD Anthrax Phase 1 Phase 1 data showed limited response.
$123.68
+0.64  +0.52%
224.2 million
$27.7 billion
07/16/2019
Tap to view 9 drugs
Drug Indication Stage News
CAEL‐101 AL amyloidosis Phase 2/3 Phase 2b/3 trial to be initiated early 2020.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Approved FDA Approval announced June 27, 2019.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) PDUFA priority review PDUFA data under priority review October 19, 2019.
ULTOMIRIS (ravulizumab-cwvz) Paroxysmal nocturnal hemoglobinuria (PNH) Approved FDA approval announced December 21, 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
ALXN1840 (WTX101) Wilson disease Phase 3 Phase 3 enrolment to be completed early 2020.
ULTOMIRIS (ravulizumab-cwvz) Generalized myasthenia gravis (gMG) Phase 3 Phase 3 trial initiated 1Q 2019.
ALXN1830 Warm autoimmune hemolytic anemia (WAIHA) Phase 1/2 Phase 1b/2a trial to be completed in 2019.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 PK data due early 2020.
$9.10
-0.13  -1.41%
33.8 million
$307.3 million
07/16/2019
Tap to view 6 drugs
Drug Indication Stage News
AMAG-423 / Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 top-line data due mid-2020.
Vyleesi (Bremelanotide) Female sexual dysfunction (FSD) Approved FDA approval announced June 21, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
Makena Preterm birth Phase 3 Phase 3b trial did not meet co-primary endpoints - March 8, 2019.
Ciraparantag Anticoagulated reversal agent / Healthy volunteers Phase 2 Phase 3a trial to be initiated 2H 2019.
AMGN Amgen Inc.
$176.74
+0.62  +0.35%
609.9 million
$107.8 billion
07/16/2019
Tap to view 28 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 data due 2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
CNP 520 Alzheimer’s Disease Phase 3 Phase 3 ongoing. Expected completion 2024.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 data released January 24, 2019 - primary endpoint met.
ABP 980 (Kanjinti; trastuzumab-anns) Herceptin biosimilar CRL FDA approval announced June 13, 2019.
ABP 710 REMICADE biosimilar - rheumatoid arthritis PDUFA BLA filing announced December 17, 2018. Estimated PDUFA date December 16, 2019.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis Approved FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 completion of enrolment announced July 15, 2019 with second interim analysis due 1H 2020.
Omecamtiv mecarbil METEORIC-HF Acute heart failure Phase 3 Second Phase 3 trial initiation announced February 21, 2019.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 330 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1 Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim) Immune Thrombocytopenia (Pediatric) Approved FDA approval announced December 14, 2018.
Nplate (Romiplostim) Immune thrombocytopenia (ITP) PDUFA sNDA filing announced December 19, 2018. Estimated PDUFA date October 18, 2019.
KYPROLIS (CANDOR) Multiple Myeloma Phase 3 Phase 3 data due 2019.
AMG 594 Healthy volunteers Phase 1 Phase 1 trial initiation announced February 20, 2019.
AMG 510 Solid tumors Phase 1 Phase 1 data at ASCO June 3, 2019. 50% ORR in lung cancer patients. 90% SD.
CNP520 Alzheimer’s Disease Phase 2/3 Phase 2/3 trial discontinued due to lack of efficacy.
$0.40
  +-0.64%
141.7 million
$57.1 million
8.82
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 Phase 3 trial to be initiated under SPA - noted June 14, 2019.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
$20.32
+0.13  +0.64%
47.1 million
$956.4 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$21.61
-0.26  -1.19%
330.7 million
$7.1 billion
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
Vascepa High Triglycerides With Mixed Dyslipidemia PDUFA priority review PDUFA date under priority review September 28, 2019.
$3.48
-0.03  -0.85%
298.8 million
$1 billion
4.65
07/16/2019
Tap to view 1 drug
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 data due 1H 2020.
$54.84
-0.82  -1.47%
27 million
$1.5 billion
07/16/2019
Tap to view 5 drugs
Drug Indication Stage News
ANB020 - etokimab Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data due 2H 2019.
ANB020 - etokimab Severe adult eosinophilic asthma Phase 2a Phase 2b trial to be initiated 2019.
ANB019 Palmo-plantar pustular psoriasis Phase 2 Phase 2 data due 1H 2020.
ANB019 Generalized pustular psoriasis Phase 2 Phase 2 data due mid-2019.
ANB020 - etokimab Nasal polyps Phase 2 Phase 2 data due 2H 2019.
$4.30
  +0.00%
6.8 million
$29.3 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
Inodiftagene - Codex Non-muscle invasive bladder cancer (NMIBC) Phase 2 Phase 2 pivotal initial data due 4Q 2019.
Inodiftagene with BCG - Leo Non-muscle invasive bladder cancer (NMIBC) Phase 3 Phase 3 planned for 2019.
$40.53
+0.19  +0.47%
14.2 million
$575.8 million
07/16/2019
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018. Noted February 21, 2019 that further Phase 3 trial is required.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 enrollment to be completed by the end of 2018.
$4.16
-0.01  -0.24%
20.1 million
$83.6 million
07/16/2019
Drug Indication Stage News
$26.31
+0.07  +0.28%
63.2 million
$1.7 billion
07/16/2019
Tap to view 6 drugs
Drug Indication Stage News
Discovery (APL2-201) Complement-dependent Nephropathies (CDN) Phase 2 Phase 2 data due 2019.
APL-2 subcutaneous Auto-immune Hemolytic Anemia (AIHA) and Cold agglutinin disease (CAD) Phase 2 Phase 2 data released June 15, 2019
APL-2 PHAROAH Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1b Phase 1b trial ongoing.
APL-2 OAKS Geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 3 Phase 3 enrolment to be completed 1Q 2020.
APL-2 subcutaneous PEGASUS Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 3 Phase 3 data due December 2019.
APL-2 PADDOCK Paroxysmal Nocturnal Hemoglobinuria Phase 1 Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
$8.36
-1.06  -11.25%
17.1 million
$142.6 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
AT-001 Diabetic cardiomyopathy (DbCM) Phase 2/3 Phase 2/3 trial to be initiated late-2019.
AT-007 Galactosemia Phase 1 Phase 1 trial initiation announced June 24, 2019.
$2.92
+0.05  +1.74%
55.4 million
$161.9 million
07/16/2019
Tap to view 2 drugs
Drug Indication Stage News
APTO-253 Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Phase 1b Phase 1b clinical hold released June 29, 2018. First patient of re-initiation announced November 26, 2018. Primary completion 1H 2020.
CG-806 Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL) Phase 1 Phase 1 safety/response data due late-2019.
$3.77
-0.04  -0.92%
33.7 million
$127.1 million
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
NYX-458 Parkinson’s Disease Cognitive Impairment (healthy volunteers) Phase 1 Phase 2 trial to be initiated 2H 2019.
NYX-2925 Fibromyalgia Phase 2 Phase 2 data released June 10, 2019 - primary endpoint met.
NYX-2925 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Phase 2 Phase 2 data released January 16, 2019 - primary endpoint not met. Additional Phase 2 trial to be initiated 2H 2019.
NYX-783 Post-traumatic stress disorder (PTSD) Phase 2 Phase 2 trial initiation announced February 19, 2019 with data due 1H 2020.
$0.85
-0.02  -1.95%
45.1 million
$38.5 million
07/16/2019
Tap to view 4 drugs
Drug Indication Stage News
APVO414 Castration-resistant prostate cancer Phase 1 Development terminated - noted November 14, 2018.
Otlertuzumab Relapsed or refractory peripheral T-cell lymphoma Phase 2 Development terminated - noted November 14, 2018.
APVO436 Acute myeloid leukemia (AML) Phase 1 Phase 1 preliminary data due 3Q 2019.
APVO210 Healthy volunteers Phase 1 Phase 1 trial initiation announced March 20, 2019 with initial single ascending doses (SAD) data due 3Q and safety data 4Q 2019.
$4.20
+0.05  +1.20%
25 million
$104.9 million
07/16/2019
Tap to view 6 drugs
<
Drug Indication Stage News
Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis PDUFA PDUFA date November 30, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures NDA Filing Rolling NDA filing has commenced - noted June 4, 2019. To be completed 4Q 2019.